Jaguar Health Inc. has recently entered into a significant financial agreement involving a privately negotiated exchange with Iliad Research and Trading, L.P. The agreement, known as the Iliad Series M Exchange Agreement, was finalized on June 27, 2025. As part of this arrangement, Jaguar Health issued 170 shares of Series M Perpetual Preferred Stock to Iliad, resulting in a $4,250,000 reduction in the outstanding balance of a previously established royalty interest. This move marks a strategic financial maneuver for Jaguar Health, aiming to optimize its financial obligations while maintaining operational flexibility.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.